Creating new drugs to treat Chagas disease
Developing methionyl tRNA synthetase inhibitors as therapeutics for Chagas disease
This study is working on creating new, safer medicines to help people with Chagas disease by targeting a specific enzyme in the parasite that causes it, aiming to improve treatment options for those who need them.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Washington NIH-funded |
| Lab location | 1 site (Seattle, United States) |
| Project ID | NIH-10594432 on NIH RePORTER |
What this research studies
This research focuses on developing inhibitors for the enzyme methionyl-tRNA synthetase found in the parasite Trypanosoma cruzi, which causes Chagas disease. Current treatments are toxic and ineffective, especially in chronic cases, so the goal is to create safer and more effective drug candidates. The researchers will optimize two promising chemical compounds through a series of rigorous tests to ensure they are potent against the parasite while being safe for human use. If successful, these new drugs could significantly improve treatment options for those affected by Chagas disease.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with Chagas disease, particularly those in the chronic stage.
Not a fit: Patients with other unrelated conditions or those who do not have Chagas disease will not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to safer and more effective treatments for Chagas disease, improving patient outcomes.
How similar studies have performed: Previous research has shown promise in developing similar inhibitors, indicating potential for success in this approach.
Where this research is happening
Seattle, United States
- University of Washington — Seattle, United States (Active)
Researchers
- Principal investigator: Fan, Erkang — University of Washington
- Study coordinator: Fan, Erkang
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.